EUROFINS CEREP-REGR (ALECR.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALECR - FR0013256518 - Common Stock
ALECR.PA Key Statistics, Chart & Performance
The current stock price of ALECR.PA is 16100 EUR. In the past month the price decreased by -19.5%. In the past year, price increased by 215.69%.
ALECR.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| DIM.PA | SARTORIUS STEDIM BIOTECH | 44.08 | 18.49B | ||
| 56S1.DE | SARTORIUS STEDIM BIOTECH | 43.97 | 18.44B | ||
| SRT3.DE | SARTORIUS AG-VORZUG | 49.3 | 16.83B | ||
| SRT.DE | SARTORIUS AG | 38.86 | 13.27B | ||
| QIA.DE | QIAGEN N.V. | 19.6 | 8.76B | ||
| 1SXP.DE | SCHOTT PHARMA AG& CO KGAA | 19.01 | 2.78B | ||
| EVT.DE | EVOTEC SE | N/A | 1.85B | ||
| GXI.DE | GERRESHEIMER AG | 6.38 | 813.76M | ||
| FF.MI | FINE FOODS & PHARMACEUTICALS | 10.13 | 198.98M |
Related stock screener links
About ALECR.PA
Company Profile
Eurofins-Cerep SA engages in the provision of preclinical drug research services. The company is headquartered in Celle-Levescault, Nouvelle-Aquitaine and currently employs 207 full-time employees. The company went IPO on 2010-03-19. The Company, using its BioPrint technology systems that analyzes pharmaceutical drugs on the market, those that have been withdrawn, and those that failed in the development stages, builds up predictive models of the potential of new drugs. These predictions are based on the drugs' chemical structure and their performance in vitro. The firm then offers solutions to the pharmaceutical and biotechnology sectors on reducing time and costs in the early stages of the drug development process. Clients can also gain access to some of the Company's technology by subscribing to BioPrint. The Company’s maximum revenue is generated through Exports accounts.
Company Info
EUROFINS CEREP-REGR
Le Bois l'Eveque
Celle-Levescault NOUVELLE-AQUITAINE FR
Employees: 218
Phone: 33549893000
EUROFINS CEREP-REGR / ALECR.PA FAQ
What does EUROFINS CEREP-REGR do?
Eurofins-Cerep SA engages in the provision of preclinical drug research services. The company is headquartered in Celle-Levescault, Nouvelle-Aquitaine and currently employs 207 full-time employees. The company went IPO on 2010-03-19. The Company, using its BioPrint technology systems that analyzes pharmaceutical drugs on the market, those that have been withdrawn, and those that failed in the development stages, builds up predictive models of the potential of new drugs. These predictions are based on the drugs' chemical structure and their performance in vitro. The firm then offers solutions to the pharmaceutical and biotechnology sectors on reducing time and costs in the early stages of the drug development process. Clients can also gain access to some of the Company's technology by subscribing to BioPrint. The Company’s maximum revenue is generated through Exports accounts.
What is the current price of ALECR stock?
The current stock price of ALECR.PA is 16100 EUR. The price decreased by -9.04% in the last trading session.
Does EUROFINS CEREP-REGR pay dividends?
ALECR.PA does not pay a dividend.
How is the ChartMill rating for EUROFINS CEREP-REGR?
ALECR.PA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the PE ratio for ALECR stock?
The PE ratio for EUROFINS CEREP-REGR (ALECR.PA) is 22.52. This is based on the reported non-GAAP earnings per share of 715 and the current share price of 16100 EUR.
Can you provide the market cap for EUROFINS CEREP-REGR?
EUROFINS CEREP-REGR (ALECR.PA) has a market capitalization of 161.00M EUR. This makes ALECR.PA a Micro Cap stock.
Can you provide the ownership details for ALECR stock?
You can find the ownership structure of EUROFINS CEREP-REGR (ALECR.PA) on the Ownership tab.
ALECR.PA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ALECR.PA. When comparing the yearly performance of all stocks, ALECR.PA is one of the better performing stocks in the market, outperforming 98.61% of all stocks.
ALECR.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ALECR.PA. ALECR.PA has an average financial health and profitability rating.
ALECR.PA Financial Highlights
Over the last trailing twelve months ALECR.PA reported a non-GAAP Earnings per Share(EPS) of 715. The EPS decreased by -6.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.86% | ||
| ROA | 9.29% | ||
| ROE | 10.82% | ||
| Debt/Equity | 0 |